Home › Oligodendroglioma › Massachusetts
Oligodendroglioma clinical trials in Massachusetts
4 studies for Oligodendroglioma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07703436Implantable Microdevice In Primary Brain Tumors
- Brigham and Women's Hospital, Boston
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT04135807SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Study of Olutasidenib and Temozolomide in HGG
- Susan Chi, Boston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.